|March 12, 2021
US FDA: Coronavirus (COVID-19) Update: March 12, 2021
The U.S. Food and Drug Administration (FDA) continued to act in the ongoing response to the COVID-19 pandemic:
As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Cannafyl for selling unapproved products with fraudulent COVID-19 claims. The company sells CBD-containing products, including “Balance CBD Drops,” “Relief CBD Drops,” “Relax CBD Drops” and “Relief CBD Salve,” and misleadingly represents the products can mitigate, prevent, treat, diagnose or cure COVID-19 in people. The FDA requested that Cannafyl take immediate action to cease the sale of any unapproved and unauthorized products for the treatment or prevention of COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.
Today, the FDA issued a Letter to Clinical Laboratory Staff, Point-of-Care Facility Staff and Health Care Providers to alert them that false positive results can occur with the Roche Molecular Systems, Inc. cobas SARS-CoV-2 & Influenza A/B Nucleic Acid Test for use on the cobas Liat System.
Today, the FDA issued an Emergency Use Authorization (EUA) for Propofol-Lipuro 1% injectable emulsion for infusion to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit setting during the COVID-19 public health emergency. Propofol-Lipuro 1% injectable emulsion for infusion is not FDA-approved and has important differences in its formulation compared to FDA-approved propofol drugs; providers should consult the Health Care Provider Fact Sheet for more information before administering it.
As of today, 341 tests and sample collection devices are authorized by the FDA under EUAs. These include 254 molecular tests and sample collection devices, 72 antibody and other immune response tests and 15 antigen tests. There are 38 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, two antigen prescription at-home test, one OTC at-home antigen test and one OTC molecular test.
More FDA COVID-19 updates can be found here.< Previous Article | Next Article >
[ return to top ]
ensure delivery of Maine Medicine Weekly Update,
please add 'email@example.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm
For more information or to contact us directly, please visit www.mainemed.com | ©